ResMed Inc.
0KW4.L
London Stock Exchange224.58
USD
-0.89
- -
ResMed Inc.
0KW4.L
(London Stock Exchange)
Recent
price
224.58
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ResMed Inc. (NYSE: RMD; ASX: RMD; LSE: 0KW4) develops, manufactures, markets and distributes cloud-connected medical devices, digital health technologies and out-of-hospital software platforms that diagnose, treat and manage sleep apnea, COPD, respiratory diseases and related chronic conditions for patients and healthcare providers worldwide. The company offers CPAP and APAP devices including the AirSense series; masks and accessories such as the AirFit nasal, full-face and pillow lines; bilevel devices and ventilators for respiratory care; patient engagement apps like myAir; remote monitoring platforms including AirView; and SaaS solutions for homecare management such as Brightree, serving sleep-disordered breathing, overlap syndrome, obesity hypoventilation, neuromuscular diseases and post-acute care in over 140 countries. Founded in 1989 in Sydney, Australia and headquartered in San Diego, California, ResMed operates through Sleep and Respiratory Care as well as Software as a Service segments, with global manufacturing including facilities in Malaysia and a focus on AI-powered data from over 27 million cloud-connectable devices. Recent developments include the May 2025 acquisition of VirtuOx, a leading independent diagnostic testing facility for at-home sleep, respiratory and cardiac services, enhancing virtual care pathways and diagnostic access; fiscal year 2025 revenue growth to approximately $4.7 billion driven by connected devices amid competitor recalls; and ongoing expansion of digital health ecosystems with over 8.8 million myAir users and 33 million patients in AirView monitoring.